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Effects of vitamin D in the elderly population:
current status and perspectives
Olivier Bruyère1*, Etienne Cavalier2, Jean-Claude Souberbielle3, Heike A Bischoff-Ferrari4,5, Charlotte Beaudart1,
Fanny Buckinx1, Jean-Yves Reginster1 and René Rizzoli6
Abstract
Besides its well-known effect on bone metabolism, recent researches suggest that vitamin D may also play a role in the
muscular, immune, endocrine, and central nervous systems. Double-blind RCTs support vitamin D supplementation at
a dose of 800 IU per day for the prevention of falls and fractures in the senior population. Ecological, case–control and
cohort studies have suggested that high vitamin D levels were associated with a reduced risk of autoimmune diseases,
type 2 diabetes, cardio-vascular diseases and cancer but large clinical trials are lacking today to provide solid evidence
of a vitamin D benefit beyond bone health. At last, the optimal dose, route of administration, dosing interval and
duration of vitamin D supplementation at a specific target dose beyond the prevention of vitamin D deficiency need
to be further investigated.
Background
The role of vitamin D in bone health has been known
for over a century. More recent researches suggest that
vitamin D may also play a role in the muscular, immune,
endocrine, and central nervous systems. The objective of
the current paper is to critically review observational and
interventional studies on the potential effect of vitamin D
on health outcomes among the elderly population. The
vitamin D assays and the optimal vitamin D level are also
discussed.
Vitamin D assay and thresholds of vitamin D
status
If all experts now agree that 25-hydroxy-vitamin D (25
(OH)D) is the biomarker of choice to evaluate patients’
vitamin D status, the level of 25(OH)D that would be
considered “normal” is more debated. Indeed, as the
level of 25(OH)D fluctuates according to seasons, the ref-
erence ranges observed in “healthy” populations should
be different in summer vs. winter, which does not make
sense. Accordingly, all experts agree that a threshold defin-
ing vitamin D deficiency should be determined in relation
to clinical outcomes, i.e. a value below which a detriment
for health could be expected. This threshold is different
whether we consider the general population or diseased
patients. For the first ones, the Institute of Medicine rec-
ommends a target of 20 ng/mL and proposes Reference
Dietary Intakes (RDI) that should help 97.5% of the popu-
lation to reach this level [1]. These RDIs are of 400 IU
from birth to 1 year old, 600 IU from 1 to 70 years old
and 800 IU above 70 years. It should be noted, however,
that other references intake values have been suggested
based on other methodologies [2]. Anyway, in western
populations, with a light sunshine exposure, no UVB syn-
thesis from late fall to early spring and a diet containing
limited amounts of vitamin D, a basic supplementation of
400–600 IU per day should thus be necessary to achieve
these goals, at least in winter. It should be noted that this
supplementation could be performed without preliminary
25(OH)D determination as the 20 ng/mL threshold is only
a recommendation (no harm will happen if the subject
presents a value slightly lower or higher than 20 ng/mL)
and the doses proposed are totally safe.
For patients, and particularly for patients presenting kid-
ney, bone or phosphocalcic disorders, many experts con-
sider however that this 20 ng/mL threshold is too low [3].
They thus suggest a target of 30 ng/mL, according to
different levels of proof, like the relation between para-
thormone (PTH) and vitamin D (even if the results from
the studies show a substantial heterogeneity in this rela-
tionship), the prevalence of signs of mineralization defects
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below 30 ng/mL [4] or, most importantly, the levels reached
by patients in treated group of randomized controlled trials
showing a positive effect of vitamin D vs placebo (mainly
studies on fracture or risk or fall prevention [5,6]). In this
context, there is some evidence that a benefit is expected
if the patient’s 25(OH)D level is higher than the cut-off
and a monitoring of 25(OH)D levels is thus mandatory.
Recently, the European Society for Clinical and Economic
Aspects of Osteoporosis and Osteoarthritis (ESCEO) rec-
ommended that 50 nmol/L (i.e. 20 ng/mL) should be the
minimal serum 25-(OH)D concentration at the population
level and in patients with osteoporosis to ensure optimal
bone health [7]. However, ESCEO also states that in fra-
gile elderly subjects who are at elevated risk for falls and
fracture, a minimal serum 25-(OH)D level of 75 nmol/L
(i.e. 30 ng/mL) should be reached for the greatest impact
on fracture. The doses necessary to reach the target of
30 ng/mL are definitively higher than the ones necessary
to obtain 20 ng/mL. They can reach 800–2000 IU per day
or 24000–60000 IU per month, and require a control
3 months after initiation of the treatment, when a plateau
is reached. According to the 25(OH)D levels reached,
the doses can be tailored to maintain the patient in the
30–50 ng/mL range. This range is totally safe as it is nat-
urally obtained in populations exposed during all year to
high UV radiation, like the Maasaï, who present a mean
25(OH)D concentration of 46 ng/mL with extreme values
ranging from 25 to 75 ng/mL [8]. Compliance of the pa-
tient with the treatment is however problematic and yearly
controls should be performed. Daily, weekly or monthly
doses are equivalent in rising and maintaining 25(OH)D
levels and patients should choose which form they prefer.
Large, yearly doses, should however be abandoned as to-
tally non physiologic, and even potentially harmful [9].
In the nineties and early twenties, most laboratories
were using the DiaSorin RIA to assess 25(OH)D levels.
The cut-offs of 20 and 30 ng/mL are notably derived
from studies that were using this assay device. However,
the increasing number of requests has led most of the
clinical laboratories to switch to methods presenting a
larger throughput, i.e. automated immunoassays or li-
quid chromatographs coupled with two mass spectrome-
ters in tandem (LC-MS/MS). The determination of 25
(OH)D concentration is however far from an easy task
and several important problems, among which the very
high lipophilic nature of the molecule and its strong as-
sociation with its carriers, vitamin D binding protein
(VDBP) and albumin have to be overcome to correctly as-
sess the parameter [10]. VDBP can be present at different
concentrations depending on some physiological or patho-
logical conditions, like race [11], pregnancy or chronic
kidney disease, which could influence the kinetic of the
liberation of the molecule [12,13]. Vitamin D can be found
as vitamin D2 or D3 and the assay should measure both
25(OH)D2 and 25(OH)D3 [14]. Different other metabo-
lites of vitamin D can be present in the serum of the
patients at different levels, possibly interfering with either
immunoassays or LC-MS/MS methods [15]. Just like any
other immunoassays, vitamin D assays are prone to hetero-
philic antibodies interference, leading to potential spurious
results [16]. Last but not least, the lack of standardization
of the different assays remains a major problem. A world-
wide standardization program (Vitamin D Standardization
Program, VDSP), coordinated by the Centers for Disease
Control and Prevention (CDC), the National Institute of
Standards and Technology (NIST) and the University of
Ghent, Belgium, is ongoing to improve the standardization
and will certainly reduce the variation observed between
methods and laboratories in healthy individuals. Neverthe-
less, different problems will remain in special popula-
tions, like pregnant women or hemodialyzed patients,
for whom standardization seems to be less efficient
[12,13]. Moreover, neither 25(OH)D2 standardization
nor 25(OH)D2 recovery will be solved by the VDSP.
Finally, re-standardization will impact the traditional
“20” or “30” ng/mL values that are used as clinical cut-offs
to define vitamin D sufficiency. Indeed, as already men-
tioned, these cut-offs derive from studies that generally
used the DiaSorin RIA for 25(OH)D measurements. Using
these cut-offs with immunoassays or LC-MS/MS methods
that are differently calibrated is thus hazardous. Re-
standardization will reduce method-to-method variations,
but will consequently also impact the cut-off values, that
will need to be updated according to the new standard.
Effects of vitamin D on falls
In a meta-analysis of 8 double-blind RCTs including a
total of 2426 individuals aged 65 and older [6], anti-fall
benefits of vitamin D supplementation were observed
from a dose of 700 IU per day onwards. In a re-analysis
requested by the Institute of Medicine [17], when treat-
ment was the only predictor (regardless of dose level),
there was a significant reduction in the odds of falling:
OR = 0.73 [0.62, 0.87]; p = .0004. When the model was
expanded to capture the impact of both high dose and
low dose treatments, high dose vitamin D treatments
(700 to 1000 IU vitamin D per day) reduced the odds
of falling (OR = 0.66 [0.53, 0.82]; p = .0002), while low
dose vitamin D treatments did not (OR = 1.14 [0.69, 1.87];
p = .61). In the Report on Vitamin D (FCN Report (2012),
there was a 38% reduction in the risk of falling with a
treatment duration of 2 to 5 months and a sustained sig-
nificant effect of 17% fall reduction with a treatment dur-
ation of 12 to 36 months with vitamin D supplements/
doses of 700 to 1000 IU. Thus, benefits of vitamin D sup-
plementation of 700 to 1000 IU per day on fall prevention
are rapid and sustained and concern all subgroups of the
senior population [6].
Bruyère et al. Archives of Public Health 2014, 72:32 Page 2 of 10
http://www.archpublichealth.com/content/72/1/32
Effects of vitamin D on bone
Results from double-blind randomized controlled trials
Vitamin D is essential for bone growth [18,19] and bone
health preservation [20]. Higher 25(OH)D levels are as-
sociated with higher bone density in younger and older
adults [21]. Also, in various double-blind RCTs, vitamin
D supplementation increased bone density and reduced
bone loss [22,23]. In a meta-analysis summarizing the evi-
dence of 12 double-blind RCTs involving 42279 individ-
uals aged 65 and older, oral vitamin D supplementation
reduced the risk of hip fracture by 18% and the risk of any
non-vertebral fracture by 20% [5]. However, similarly to
fall prevention, the benefit on fracture prevention depends
on the dose of vitamin D. Fracture prevention required a
received dose (treatment dose*adherence) of more than
482 IU vitamin D per day. The primary use of received
dose (dose*adherence) as opposed to treatment dose from
double-blind RCTs allowed for the assessment of anti-
fracture efficacy by a dose that accounts for the low adher-
ence in several recent large trials [24,25]. Any lower
received dose than 482 IU per day did not reduce fracture
risk at either any non-vertebral site or the hip. Similarly to
the data on fall prevention with vitamin D, at the highest
received dose of vitamin D (>482 IU per day) the preven-
tion of non-vertebral fractures was present in all sub-
groups of the older population independently of age and
type of dwelling [5]. Notably, there was a suggestion that
vitamin D3 was superior to vitamin D2 for both fall and
fracture prevention [5,6].
A participant level meta-analysis from 11 double-blind
RCTs (31022 individuals with mean age 76 years, 91%
women sustaining 1111 incident hip and 3770 non-
vertebral fractures) assessed the effect of actual dose of
vitamin D on fracture reduction. Actual dose considered
adherence to treatment and additional vitamin D intake
outside the study medication. In this pooled analysis,
fracture reduction was only present at the highest actual
intake of 800 IU of vitamin D per day (range: 792 to
2000 IU/d) with a 30% reduction at the hip and 14% re-
duction at any non-vertebral site independently of vitamin
D treatment, age group, gender, type of dwelling and study
[26]. This study further suggested that the typical intent-
to-treat results for vitamin D, which was replicated by the
authors with a non-significant 10% reduction at the hip
and 7% reduction at any non-vertebral site, may underesti-
mate the benefit of vitamin D supplementation and ex-
plain the conflicting results of other meta-analyses [26].
Results from meta-analyses on fracture prevention that
also included open-design trials
A review and meta-analysis commissioned by the US
Department of Health and Human Services (HHS) has
addressed the effect of vitamin D supplementation on all
fractures in postmenopausal women and men aged 50
and older [27]. The pooled results for all fractures in-
cluded 10 double-blinded and 3 open design trials (n =
58712). However, it did not support a significant reduction
of fractures with vitamin D (pooled odds ratio = 0.90; 95%
CI 0.81-1.02). The report suggested that the benefit of
vitamin D may depend on additional calcium and may be
primarily seen in institutionalized individuals, which is
consistent with the meta-analysis of Boonen et al. [28].
The DIPART group conducted a patient-based meta-
analysis including 7 large trials on vitamin D with 68500
individuals aged 47 and older [29] : two open design tri-
als [30,31], one trial with intra-muscular vitamin D, and
4 of the 10 double-blind RCTs included in the 2009
meta-analysis described above (one RCT using intermit-
tent vitamin D2 doses without calcium [32], one RCT
with 400 IU of vitamin D3 without calcium [33], one
trial with 800 IU of vitamin D3 per day with and without
calcium and less than 50% adherence [25], and one trial
with 400 IU of vitamin D with calcium [24]). On the
basis of the inclusion criteria, a reduced overall risk of
fracture (hazard ratio = 0.92; 95% CI 0.86 to 0.99) and
a non-significant reduction of hip fractures (hazard
ratio = 0.84; 95% CI 0.70 to 1.01) was found for trials
that used vitamin D plus calcium. Vitamin D supplemen-
tation alone, irrespective of dose, did not reduce fracture
risk. It was concluded that vitamin D, even in a dose of
400 IU of vitamin D per day reduces the risk of fracture if
combined with calcium. Notably, this regimen was tested
in 36282 postmenopausal women in the Women’s Health
Initiative Trial over a treatment period of 7 years and did
not reduce the risk of fracture [24].
A most recent 2014 trial-level meta-analysis (76497 par-
ticipants) was based on a mix of trials with blinded and
open designs, follow-up periods that were as short as
1 month, administered doses and compliance that ranged
widely, and endpoints that ranged from primary to second-
ary along with un-pre-specified, and consequently were
adjudicated and non-adjudicated. However, despite the
great variety and mixed quality of trials, the authors docu-
mented a significant 8% reduction for total fractures and a
significant 16% reduction for hip fractures for vitamin D
plus calcium supplementation [34].
Discussion on the meta-analyses that also included
open-design trials
In all 3 meta-analyses reviewed above, dose heterogeneity
may have been missed due to the inclusion of open design
trials plus a dose evaluation that did not incorporate adher-
ence to treatment. A dose–response relationship between
vitamin D supplementation and fracture reduction as doc-
umented for the two 2009 meta-analyses of double-blind
RCTs [5,6], is supported by epidemiologic data showing a
significant positive trend between serum 25(OH)D concen-
trations and hip bone density [21] and lower extremity
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strength [35,36]. Factors that may obscure the benefit of
vitamin D supplementation are low adherence to treat-
ment [25], too low doses of vitamin D, or the use of the
less potent vitamin D2 [37,38]. Furthermore, open design
trials [30] may bias results towards the null because vita-
min D is available over the counter.
Conclusion on falls and fractures
Based on evidence from RCTs, oral vitamin D supple-
mentation reduces both falls and non-vertebral fractures,
including those at the hip. However, these benefits are
dose-dependent and a dose of 700–1000 IU of vitamin
D per day is required to assure both fall and fracture pre-
vention in older adults.
Effects of vitamin D on muscle
Proximal muscle weakness is a prominent feature of the
clinical syndrome of vitamin D deficiency [39]. Muscle
manifestations such as proximal muscle weakness, diffuse
muscle pain and gait impairments are well-known clinical
symptoms of vitamin D deficiency [40]. The activation of
vitamin D receptors (VDRs), which is expressed in human
muscle tissue [41,42] appears to stimulate protein synthe-
sis in muscle [43]. Smaller and variable muscle fibres and
persistence of immature muscle gene expression during
adult life are found in mice lacking VDR [44]. These ab-
normalities persist after correction of systemic calcium
metabolism by a rescue diet, whereas the bone phenotype
is normalized after correction of calcium and phosphate
plasma concentrations [45].
Most observational studies show a positive association
between higher 25(OH)D status and better lower extrem-
ity function in older adults, a lower risk of functional de-
cline [35,46], a lower risk of future falls and a lower risk of
nursing care admission [47], including two population-
based studies from the US [36] and Europe [35].
Consistently, in several trials of older individuals at
risk for vitamin D deficiency, vitamin D supplementation
improved strength, function, and balance [48-50]. Most
importantly, these benefits translated in a reduction in
falls in some of the same trials [48-50]. In three recent
double-blind RCTs supplementation with 800 IU vitamin
D3 resulted in a 4-11% gain in lower extremity strength
or function [48,50], and an up to 28% improvement in
body sway [48,49] in older adults aged 65 and older
within 2 to 12 months of treatment. Extending to trials
among individuals with a lower risk of vitamin D defi-
ciency and including open design trials, a recent meta-
analysis by Stockton identified 17 RCTs that tested any
form of vitamin D treatment and documented a muscle
strength related endpoint. The authors suggested that
based on their pooled findings, vitamin D may not im-
prove grip strength, but a benefit of vitamin D treat-
ment on lower extremity strength could not be excluded
(p = 0.07) among individuals with 25(OH)D starting levels
of > 25 nmol/l and the authors report a significant benefit
among two studies with participants that started with
25(OH)D levels < 25 nmol/l [51]. In a more recent meta-
analysis of Muir and Montero-Odasso, 13 randomized
controlled trials were identified in seniors aged 60 years
and older. In the pooled analysis, vitamin D supplementa-
tion had a significant benefit on postural sway and lower
extremity mobility measured with the timed up and go
and lower extremity strength [52].
Mechanistically, it has been suggested that 1,25-
dihydroxyvitamin D binds to the nuclear VDR in muscle
resulting in de novo protein synthesis [53,54]. At a clinical
level, this is supported by findings of three small trials in
older adults, which documented an increase in type II
muscle fibres after treatment with 1-alpha-calcidiol [43]
or vitamin D2 [55] or vitamin D3 [56].
Consequently, evidence supports the use of vitamin D
supplementation to improve muscle strength and func-
tion but additional studies may be needed to define the
optimal treatment dose.
Other potential effects of vitamin D in the elderly
population
Many tissues without any obvious relationship with the
calcium/phosphorus and/or bone metabolism are able to
express the VDR, 1-alpha-hydroxylase, and 24-hydroxylase
molecules. 25(OH)D enters these tissues and is locally hy-
droxylated into calcitriol which binds to the VDRs present
in these cells. This “peripheral” production of calcitriol is
not regulated by calciotropic hormones (PTH, FGF23, …),
but seems dependent on the 25(OH)D concentration in
the extra-cellular fluid of these tissues. This is the basis for
the “non-classical” genomic effects of vitamin D that could
be considered as “intracrine” by contrast with the classical
endocrine effects of calcitriol. We also know that plasma
calcitriol can exert rapid non genomic effects in some tis-
sues such as muscle fibres or pancreatic beta-cells where it
binds to membrane proteins resembling the VDR [57].
In addition to its effects on calcium/phosphorus metab-
olism, non vertebral fractures and falls, vitamin D may
exert various other effects as suggested by numerous ob-
servational studies that reported positive associations be-
tween vitamin D deficiency (i.e. low circulating levels of
25(OH)D) and an increased risk for many diseases that
remained significant after adjustment for confounders.
Among these potential non classical effects, some may be
highly relevant to the elderly.
 Vitamin D deficiency is associated with an increased
risk for different cancers, especially colorectal [58]
and breast [59].
 Globally, many experimental studies support the
suppression of acquired immunity and the
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stimulation of innate immunity by vitamin D. VDRs
and 1-alpha hydroxylase are present in T and B
lymphocytes, macrophages and antigen-presenting
cells. Calcitriol reduces the proliferation of the
T-lymphocytes, especially T-helper 1 (Th1) and
Th17 lymphocytes and the production of certain
cytokines with inflammatory properties. On the
other hand calcitriol stimulates the production of
other cytokines with anti-inflammatory actions such
as IL10 and favours Th2 and regulatory T lymphocytes
phenotypes. This modulation of acquired immunity is
believed to be beneficial in a number of auto-immune
diseases as suggested by studies showing that vitamin
D deficiency is associated with higher incidence and
poorer outcomes of some auto-immune diseases [60],
and to have global anti-inflammatory effects [61] that
could be of help in many diseases as an adjunct to
usual therapy [62]. As regards innate immunity, it is
now known that macrophages or monocytes exposed
to an infectious agent such as bacillus tuberculosis
overexpress Toll-like receptors, VDRs, and 1-alpha
hydroxylase. Provided that the 25(OH)D concentration
in the cell’s extracellular liquid is sufficient, they
produce 1,25(OH)2D which binds to the VDRs
inducing the production of antimicrobial peptides
such as cathelicidin which contributes to the
destruction of the infectious agent [63]. This
mechanism may explain partly the relationship
between the frequency of some infectious diseases
and low 25(OH)D concentrations found in
epidemiological studies [64].
 Vitamin D deficiency has not only been found to
be associated with an increased risk of major
cardio-vascular events but also with cardio-vascular
mortality in several studies [65]. Potential mechanisms
are complex and involve both direct effects of vitamin
D on vascular endothelial cells, and indirect effects
through the control of the renin-angiotensin system
and thus blood pressure, on the PTH secretion,
insulin secretion and sensitivity, and inflammation [66].
 In non-dialyzed patients with chronic kidney disease,
vitamin D deficiency is associated with albuminuria
and a more rapid deterioration of renal function [67].
 Lower serum vitamin D concentrations are found in
patients with Alzheimer’s disease compared to
matched controls [68], and predict executive
dysfunction in community-dwellers [69].
 Finally, vitamin D sufficiency is associated with a
delayed mortality not only in prospective
observational studies [70], but also in interventional
studies, especially when associated with calcium [71].
These potential “non-classical” effects of vitamin D seem
so impressive that a discussion on the level of evidence
supporting them is necessary. Indeed, “association” does
not mean “causality”, and it must be recognized that the ef-
fects mentioned above in the previous paragraph are
mostly documented by observational (often prospective
however) and experimental (cell culture, animal models…)
studies. One important question is to know whether vita-
min D supplementation is able to improve all or part of
the disease/anomalies associated with vitamin D defi-
ciency or whether the above-mentioned associations only
reflect a poor health status. Several RCTs showing a better
effect of vitamin D supplementation compared to placebo
on these diseases or their complications exist to-date (see
for example [72-79]). The results of these positive RCTs
are however generally not applicable to the general popu-
lation as they were targeted to specific groups [76-78], or
were the results of secondary objectives of studies that
had been designed to study another function [72], or con-
cerned intermediate parameters and not “hard” (clinical)
end-points [73-75,79]. Furthermore, numerous RCTs have
been “null” in that they showed no benefit, but also no dis-
advantage compared to placebo. To our knowledge, only
two studies on the risk of fracture in elderly subjects that
used very large vitamin D doses administered at very large
intervals were “negative” (i.e. worse results in the vitamin
D groups than in the placebo groups [9,80]). Reasons that
may explain the discrepancies between the results of these
various studies are several. Among the most frequently
cited are the use of vitamin D doses that are too low to
expect any effect, a poor observance, and inclusion of
subjects who were not vitamin D deficient. It must be ac-
knowledged that when the RCTs that have tested the non
classical effects of vitamin D (i.e. effects other than those on
fractures, falls, and improvement of the calcium/phosphorus
metabolism) are grouped in meta-analyses and evaluated
according to an intent-to-treat analysis, no (or very min-
imal at best) effects of vitamin D could be ascertained
[81]. Intent-to-treat analysis, which is necessary for a rele-
vant evaluation of drugs according to the “Evidence-based-
Medicine” concept, should however not be systematically
applied to the evaluation of vitamin D effects which is not
a drug stricto sensu (as well as to any other nutriment), or
should be at least adapted. Having said that, we know that
RCTs will remain the gold standard to definitely conclude
that the above-discussed non classical effects of vitamin D
are a reality. It seems thus important to define the condi-
tions that will allow the best interpretation of the data (see
Table 1 for a tentative suggestion of a list).
Discussion
Three elements deserve further discussion.
Dosing intervals
In 2010, a large double-blind RCT by Sanders et al., in-
cluded 2256 community-dwelling women aged 70 years
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and older, to test the benefit of 500000 IU of vitamin D3
given orally once a year, on fall and fracture prevention [9].
In those women, mean age 76, considered to be at risk of
fracture, 500000 IU of vitamin D once a year did not re-
duce, but instead increased the risk of falls by 15% and the
risk of fractures by 26% compared to placebo, with the
greatest increase in falls occurring during the first 3 months
after dosing. These findings are consistent with another
trial that tested 300000 IU of vitamin D2 as an intra-
muscular injection once a year [80]. The temporal pattern
of events may suggest that the high dose of vitamin D may
have induced a “protective” reaction resulting in an acute
decrease in 1,25-dihydroxyvitamin D [82]. Alternatively,
the undocumented potential effect of vitamin D on muscle
strength [36] and overall health (i.e. less infections and less
hospital admissions [83]) in the Sanders trial, may have
been an improvement in mobility which has ironically, led
to increase opportunities to fall and fracture. As a result of
the Sanders trial and given that the half-life of vitamin D is
3 to 6 weeks, a daily, weekly, or monthly dosing interval
may be more advantageous and safer [84,85].
How to promote optimal vitamin D status
Studies suggest that supplementation of 700 to 1000 IU of
vitamin D per day may bring the concentration in 25(OH)
D of 50% of younger and older adults up to 75–100 nmol/L
[86-88] Individuals with a lower starting level may need a
higher dose of vitamin D to achieve desirable levels, while
relatively lower doses may be sufficient in individuals who
start at higher baseline levels. Due to seasonal fluctuations
of 25(OH)D levels [89], some individuals may be in the
desirable range during summer months, but their levels
will not sustain during the winter months, even in sunny
latitudes [90,91]. Furthermore, several studies suggest that
many older persons will not achieve optimal serum 25(OH)D
levels during summer months suggesting that, among this
population, vitamin D supplementation should be independ-
ent of season [91-93]. Even among younger persons, the use
of sunscreen or sun-protective clothing may prevent a sig-
nificant production of 25(OH)D [93]. Most vulnerable to
low vitamin D levels are older individuals [91,94], individuals
living in northern latitudes with prolonged winters [89,95],
obese individuals [96], and individuals of all ages with dark
skin pigmentation living in northern latitudes [21,97,98].
Naturally high 25(OH)D levels observed in healthy outdoor
workers are 135 nmol/L [99] in farmers and 163 nmol/L
[100] in lifeguards. As a first sign of toxicity, only serum
25(OH)D levels of above 220 nmol/L have been associated
with hypercalcemia [101,102].
Reverse causality and confounding factors in
observational studies
When analysing results of observational studies, it is im-
portant to consider potential reverse causality or residual
confounding factors. For example, lifestyle factors, not al-
ways adequately recorded in observational studies, could
influence circulating levels of vitamin D and, as such,
could confound the association between 25(OH)D levels
and incidence of diseases. On the other hand, 25(OH)D
levels might not be responsible for the changes in out-
comes of the diseases but disability in itself might influ-
ence the vitamin D status of the individual. In other
words, serum 25(OH)D levels could just be a biomarker
of severity of the diseases. In principle, these issues with
reverse causality and confounding factors could be ruled
out with RCTs.
Table 1 Parameters and conditions that should be controlled for an optimal evaluation of the effects of vitamin D in
future RCTs
Conditions Actions
Conditions allowing an optimisation
of the statistical power of the study
(common conditions for trials of
drugs and nutrients)
Sample size (number of participants) and trial duration must be appropriately calculated according to the frequency
of the studied event in the recruited population. These points depend on the basal clinical status of the patients
(larger sample and/or longer duration if the studied disease is not very active in the recruited patients)
Adherence/observance must be optimized (for example, new technologies such as SMS that are sent the day just
before the treatment must be taken, in case of intermittent dosage, allow an easy reminding for the patients)
Conditions specific to a vitamin D trial Choose to administrate vitamin D3 instead of D2, specially in case of intermittent dosage
Ensure that dietary calcium intakes of the participants are sufficient
Treat with daily doses or, in case of intermittent dosage, choose doses that are not too high (<or = 100000
IU) and not too spaced out (ideally < or = 1 month)
Choosing the dose will depend on the disease to be studied (search in the literature) but must be above
800 IU/day (often more)
Possible vitamin D supplements that were taken by the patients before the study must be stopped
(paradoxically, it was found in some studies with a poor observance that some patients in the placebo
group received in fact more vitamin D during the trial than some patients in the vitamin D group)
It will be important to recruit patients with low 25OHD serum levels (or at least much lower than the 25OHD
levels that are targeted in the study) so that a frank increase of the 25OHD concentration may be observed
on the one hand, and so that the placebo group is really insufficient/deficient on the other hand.
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Conclusion
Results from ecological, case–control and cohort studies
have shown that high vitamin D levels were associated
with a reduced risk of bone fracture, falls, autoimmune
diseases, type 2 diabetes, cardio-vascular diseases and can-
cer. Since the prevalence of vitamin D inadequacy is high,
supplementation with vitamin D has then been recom-
mended, especially in high risk and elderly population.
Notably, evidence from double-blind RCTs support vita-
min D supplementation at a dose of 800 IU per day for
the prevention of falls and fractures in the senior popula-
tion. Further, several studies reviewed in this paper suggest
a potential effect of vitamin D in human health but large
clinical trials are lacking today to provide solid evidence
of a vitamin D benefit beyond bone health at all ages and
fall prevention in the senior population. Additionally, the
optimal dose, route of administration, dosing interval and
duration of vitamin D supplementation at a specific target
dose beyond the prevention of vitamin D deficiency needs
to be further investigated. It is possible that the optimal
level of vitamin D should be individualized, based on clin-
ical and demographic characteristics of the subject and
outcome.
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